Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease (Q33843641)

29 July 2017

1 reference

title

Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease (English)

1 reference

29 July 2017

1 reference

coronary artery disease

1 reference

2

Topol EJ

1 reference

29 July 2017

Bhatt DL

1

1 reference

29 July 2017

publication date

1 January 2000

1 reference

Medical Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

84

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

163-79, ix

1 reference

Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Thrombotic thrombocytopenic purpura after stenting and ticlopidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Benefit of Early Sustained Reperfusion in Patients With Prior Myocardial Infarction (The GUSTO-I Trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Do “America's Best Hospitals” Perform Better for Acute Myocardial Infarction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Epidemic of cardiovascular disease and stroke: the three main challenges. Presented at the 71st scientific sessions of the American Heart Association. Dallas, Texas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Are we mortgaging the medical profession?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Development of aspirin resistance in persons with previous ischemic stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin response and failure in cerebral infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Adverse haematological effects of ticlopidine. Prevention, recognition and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Cardiology. Attention shifts to the white clot

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Thrombotic thrombocytopenic purpura related to ticlopidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Final report on the aspirin component of the ongoing Physicians' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Direct medical costs of coronary artery disease in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

The antiplatelet effects of ticlopidine and clopidogrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin, heparin, or both to treat acute unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Reactivation of unstable angina after the discontinuation of heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Rash in patients receiving ticlopidine after intracoronary stent placement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

Long-term anticoagulant treatment after acute myocardial infarction. The Warfarin Re-Infarction Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970212-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(05)70212-1

1 reference

29 July 2017

1 reference